FIGURE 6.

Combined inhibition of Aurora‐A and Haspin synergistically regresses breast tumors in vivo. A. Nude mice bearing MDA‐MB‐231 xenograft tumors were treated with MLN8237 and CHR‐6494 alone or in combination. The measured tumor volume from days 0 to 21 after treatment is plotted versus time. The repeated‐measures ANOVA, followed by the least significant difference test were used to evaluate the difference between groups, n = 12; *P < 0.05; **P < 0.01; ***P < 0.001. B. Tumors removed from 6 mice in each group are shown. C. Statistical analysis of the weights of dissected tumors. The ANOVA test, followed by the least significant difference test, was used to evaluate the difference between groups, n = 12; ns, not significant; **P < 0.01; ***P < 0.001. D. The body weights of mice were measured and plotted against time, n = 6. E. Expression of AURKA and GSG2 in 994 breast cancer patient samples from the TCGA Pan‐Cancer Atlas. Pearson's correlation and linear regression analyses were employed. F and G. Relapse‐free survival and overall survival for AURKA/GSG2 transcription levels in breast cancer patients using the Kaplan–Meier plotter online tool. Abbreviations: HR, Hazard Ratio; TCGA, The Cancer Genome Atlas; 95% CI, 95% Confidence Interval